All > Georgia > Paid Studies Kentucky

GSK3511294 (Depemokimab) for Asthma

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
GSK Investigational Site, Rincon, GAAsthmaGSK3511294 (Depemokimab) - Biological
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test whether GSK3511294 is effective and safe in people with severe uncontrolled asthma that is characterized by high levels of eosinophils.

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Similar Trials

1
PET/MRI Imaging
1
Naltrexone Hydrochloride
1
hypnosis therapy

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: Baseline (Day 1) and Week 52

Week 52
Change from Baseline in Asthma Control Questionnaire-5 (ACQ-5) score at Week 52 (scores on a scale)
Change from Baseline in Saint (St.) George's Respiratory Questionnaire (SGRQ) total score at Week 52 (scores on a scale)
Change from Baseline in pre-bronchodilator forced expiratory volume in one second (FEV1) at Week 52 (liters)
Up to Week 52
Annualized rate of clinically significant exacerbations over 52 weeks
Annualized rate of exacerbations requiring hospitalization and/or ED visit over 52 weeks
Annualized rate of exacerbations requiring hospitalization and/or Emergency department (ED) visit over 52 weeks

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Similar Trials

1
PET/MRI Imaging
1
Naltrexone Hydrochloride
1
hypnosis therapy

Trial Design

2 Treatment Groups

Participants receiving GSK3511294 (Depemokimab)
1 of 2
Participants receiving placebo
1 of 2

Experimental Treatment

Non-Treatment Group

375 Total Participants · 2 Treatment Groups

Primary Treatment: GSK3511294 (Depemokimab) · Has Placebo Group · Phase 3

Participants receiving GSK3511294 (Depemokimab)
Biological
Experimental Group · 1 Intervention: GSK3511294 (Depemokimab) · Intervention Types: Biological
Participants receiving placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline (day 1) and week 52

Who is running the clinical trial?

GlaxoSmithKlineLead Sponsor
4,661 Previous Clinical Trials
7,949,980 Total Patients Enrolled
288 Trials studying Asthma
409,510 Patients Enrolled for Asthma
Iqvia Pty LtdIndustry Sponsor
95 Previous Clinical Trials
233,541 Total Patients Enrolled
4 Trials studying Asthma
2,742 Patients Enrolled for Asthma
GSK Clinical TrialsStudy DirectorGlaxoSmithKline
3,568 Previous Clinical Trials
6,133,946 Total Patients Enrolled
227 Trials studying Asthma
401,466 Patients Enrolled for Asthma

Eligibility Criteria

Age Any Age · All Participants · 11 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Who else is applying?

What state do they live in?
South Carolina66.7%
North Carolina33.3%
How old are they?
18 - 65100.0%
What site did they apply to?
GSK Investigational Site100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria100.0%
References

Frequently Asked Questions

How many test subjects are a part of this experiment?

"Yes, the information on clinicaltrials.gov suggests that this trial is actively searching for participants. The trial was initially posted on 3/17/2021 and was most recently updated on 10/18/2022. The study is enrolling 375 patients between 33 locations." - Anonymous Online Contributor

Unverified Answer

What is the margin of safety for GSK3511294 (Depemokimab)?

"GSK3511294 (Depemokimab) has been rated as a 3 in terms of safety. This is due to being a Phase 3 trial, which provides some evidence of efficacy as well as multiple rounds of data supporting its safety." - Anonymous Online Contributor

Unverified Answer

Are we still enrolling individuals for this clinical research project?

"The website clinicaltrials.gov has the most recent information on this trial, which is actively recruiting patients. The study was created on 3/17/2021 and was last edited on 10/18/2022." - Anonymous Online Contributor

Unverified Answer

How many locations are conducting this research?

"This study is enrolling at 33 sites, which are situated in and around San Antonio, Houston, and Cypress. Please choose the location most convenient for you to limit travel-related impact on your life if you decide to participate." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top